glp 1 mash approval GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat (Metabolic Dysfunction–Associated Revolutionizing MASLD treatment with GLP-1

A Customer Solutions Representative will contact you soon

Recent FDA Alerts for semaglutide Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US PLAINSBORO, NJ, December 5, 2025 - FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisks authorized supply chain

Common scenarios include achieving target weight loss goals, experiencing intolerable adverse effects such as persistent nausea or gastrointestinal disturbances, financial constraints related to medication costs, pregnancy planning or confirmation (tirzepatide should be discontinued when pregnancy is recognized), or development of contraindications

It does this partly by promoting angiogenesis the formation of new blood vessels which brings more oxygen and nutrients to damaged areas